3 Beaten-Down Biotech Stocks: Can They Recover?
The past month has been awfully hard on biotech stocks across the board. That made it an inauspicious time to report clinical trial results that were anything less than outstanding.
Apparently, these three biotech start-ups didn't get the message. All three stocks fell hard on readouts that weren't quite what investors had hoped for.
Could one of these stocks fit in a bargain-shopper's portfolio? Before you even think about trying to catch one of these falling knives, have a look at what drove these stocks lower in the first place.
Source Fool.com
